Adoptive Immunotherapy with Interleukin-2 and Interferon-alpha in Metastatic Renal Cell Cancer
Approximately one half of all newly diagnosed cancer patients will die of metastatic disease despite the application of the best available treatment consisting of surgery, radiation therapy and chemotherapy. Attempts to develop new approaches for the treatment of metastatic cancer by stimulating immune host defences against the tumor have received substantial attention. Initially most efforts to develop immunotherapies have involved nonspecific stimulation of the immune system with unspecific immunostimulants such as Bacille Calmette Guerin or Corynebacterium parvum. However, clinical trials have been disappointing and this immunotherapeutic approach has been abandoned. An alternative approach is that of adoptive immunotherapy, which is defined as the transfer of immunologic reagents or immune cells with antitumor reactivity to the tumor bearing host.
|Keywords||Interleukin-2, cancer, immunotherapy, melanoma, metastases, neoplasms, oncology, renal cancer, tumours|
|Promotor||Stoter, G. (Gerrit)|
|Publisher||Erasmus MC: University Medical Center Rotterdam|
Kruit, W.H.J.. (1996, November 27). Adoptive Immunotherapy with Interleukin-2 and Interferon-alpha in Metastatic Renal Cell Cancer. Erasmus MC: University Medical Center Rotterdam. Retrieved from http://hdl.handle.net/1765/22733